CRSPCRISPR Therapeutics AG
Biological Products, (no Diagnostic Substances)
- Revenue
- $4M
- 91% YoY
- Operating margin
- -18933.6%
- 1414% YoY
- EBITDA
- −$645M
- 44% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $295M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired21× of revenueOver 10% of revenue
- Payouts exceed cash flowClear-0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $915M | $1M | $371M | $37M | $4M | 91% |
| Operating income | $374M | −$673M | −$223M | −$467M | −$665M | 42% |
| Net income | $378M | −$650M | −$154M | −$366M | −$582M | 59% |
| Operating cash flow | $539M | −$496M | −$260M | −$143M | −$345M | 142% |
| Capex | $82M | $37M | $9M | $2M | $914K | 52% |
| Stock-based comp | $102M | $98M | $81M | $87M | $72M | 16% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $5M · 8
- Net
- −$5M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $8M | $22M | 34 | 120 |
| FY2024 | $33M | $10M | 65 | 114 |
| FY2023 | $12M | $25M | 103 | 115 |
| FY2022 | $21M | $2M | 67 | 111 |
| FY2021 | $17M | −$27M | 124 | 125 |